NKTR-118 + moxifloxacin + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Amount of NKTR-118 in Blood
Conditions
Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
Trial Timeline
Apr 1, 2011 → Jul 1, 2011
NCT ID
NCT01325415About NKTR-118 + moxifloxacin + Placebo
NKTR-118 + moxifloxacin + Placebo is a phase 1 stage product being developed by AstraZeneca for Amount of NKTR-118 in Blood. The current trial status is completed. This product is registered under clinical trial identifier NCT01325415. Target conditions include Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01325415 | Phase 1 | Completed |